Lido Advisors LLC lowered its holdings in Celgene Co. (NASDAQ:CELG) by 32.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,245 shares of the biopharmaceutical company’s stock after selling 5,011 shares during the quarter. Lido Advisors LLC’s holdings in Celgene were worth $966,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Alpine Global Management LLC purchased a new stake in shares of Celgene during the first quarter valued at $6,602,000. Zions Bancorporation N.A. purchased a new stake in shares of Celgene during the first quarter valued at $97,000. Swiss National Bank boosted its position in shares of Celgene by 2.1% during the first quarter. Swiss National Bank now owns 2,333,996 shares of the biopharmaceutical company’s stock valued at $220,189,000 after buying an additional 47,400 shares during the last quarter. Norinchukin Bank The boosted its position in shares of Celgene by 3.3% during the first quarter. Norinchukin Bank The now owns 170,931 shares of the biopharmaceutical company’s stock valued at $16,126,000 after buying an additional 5,477 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Celgene by 0.3% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 45,069 shares of the biopharmaceutical company’s stock valued at $4,251,000 after buying an additional 128 shares during the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.
A number of research firms have weighed in on CELG. Mizuho set a $103.00 target price on Celgene and gave the company a “buy” rating in a report on Friday, April 5th. Barclays downgraded Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price objective on the stock. in a research note on Friday, May 3rd. BidaskClub downgraded Celgene from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th. William Blair downgraded Celgene from an “outperform” rating to a “market perform” rating in a research note on Monday, April 1st. Finally, Atlantic Securities downgraded Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 target price on the stock. in a research note on Monday, April 1st. Nineteen analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $95.56.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.10. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. Celgene’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.05 EPS. As a group, sell-side analysts forecast that Celgene Co. will post 9.85 earnings per share for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Bear Market – How and Why They Occur
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.